Minority Views
[To accompany H.R. 485]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 485) to amend title XI of the Social Security
Act to prohibit the use of quality-adjusted life years and
similar measures in coverage and payment determinations under
Federal health care programs, having considered the same,
reports favorably thereon with an amendment and recommends that
the bill as amended do pass.
CONTENTS
Page
Purpose and Summary.............................................. 3
Background and Need for Legislation.............................. 3
Committee Action................................................. 3
Committee Votes.................................................. 4
Oversight Findings and Recommendations........................... 7
New Budget Authority, Entitlement Authority, and Tax Expenditures 7
Congressional Budget Office Estimate............................. 7
Federal Mandates Statement....................................... 7
Statement of General Performance Goals and Objectives............ 7
Duplication of Federal Programs.................................. 7
Related Committee and Subcommittee Hearings...................... 7
Committee Cost Estimate.......................................... 7
Earmark, Limited Tax Benefits, and Limited Tariff Benefits....... 8
Advisory Committee Statement..................................... 8
Applicability to Legislative Branch.............................. 8
Section-by-Section Analysis of the Legislation................... 8
Changes in Existing Law Made by the Bill, as Reported............ 8
Minority Views................................................... 138
The amendment is as follows:
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Protecting Health Care for All
Patients Act of 2023''.
SEC. 2. PROHIBITING THE USE OF QUALITY-ADJUSTED LIFE YEARS AND SIMILAR
MEASURES IN COVERAGE AND PAYMENT DETERMINATIONS
UNDER FEDERAL HEALTH CARE PROGRAMS.
(a) In General.--Section 1182(e) of the Social Security Act (42
U.S.C. 1320e-1(e)) is amended--
(1) by inserting ``or treats extending the life of an
elderly, disabled, or terminally ill individual as of lower
value than extending the life of an individual who is younger,
non-disabled, or not terminally ill'' after ``because of an
individual's disability'';
(2) by inserting ``described in the preceding sentence''
after ``such a similar measure'';
(3) by striking ``The Secretary shall not'' and inserting ``A
Federal agency (including the CMI (as described in section
1115A)) or State may not'';
(4) by striking ``under title XVIII.'' and inserting the
following: ``under any Federal health care program (as defined
in section 1128B, except that such term shall include the
health program established under chapter 89 of title 5, United
States Code).''; and
(5) by adding at the end the following new sentence:
``Notwithstanding any other provision of law, a Federal agency
(including the CMI) or State may not waive the application of
the provisions of this subsection (or the provisions of section
1852(o), section 1860D-12(h), section 1902(a)(88), section
1932(b)(9), or section 2102(e)) under section 1115, section
1115A, or any other demonstration or waiver authority.''.
(b) Conforming Amendments.--
(1) Medicaid.--
(A) In general.--Section 1902(a) of the Social
Security Act (42 U.S.C. 1396a(a)) is amended--
(i) in paragraph (86), by striking ``and'' at
the end;
(ii) in paragraph (87)(D), by striking the
period and inserting ``; and''; and
(iii) by inserting after paragraph (87) the
following new paragraph:
``(88) provide for compliance with the requirements of
section 1182(e) (relating to prohibiting the use of certain
measures in coverage determinations, reimbursement, and
incentive programs).''.
(B) Managed care organizations.--Section 1932(b) of
the Social Security Act (42 U.S.C. 1396u-2(b)) is
amended by adding at the end the following new
paragraph:
``(9) Prohibition on use of quality-adjusted life years.--The
provisions of section 1182(e) shall apply to the utilization of
a dollars-per-quality adjusted life year or similar measure (as
described in such section) by a medicaid managed care
organization under this title (or a prepaid inpatient health
plan or prepaid ambulatory health plan, as defined in section
438.2 of title 42, Code of Federal Regulations (or any
successor regulation), under a contract with the State) in the
same manner as such provisions apply to the utilization of such
a year or measure by a State under this title.''.
(2) CHIP.--Section 2102 of the Social Security Act (42 U.S.C.
1397bb) is amended by adding at the end the following new
subsection:
``(e) Prohibition on the Use of Quality-Adjusted Life Years and
Similar Measures.--A State child health plan shall provide for
compliance with the requirements of section 1182(e) (relating to
prohibiting the use of certain measures in coverage determinations,
reimbursement, and incentive programs).''.
(3) Medicare advantage.--Section 1852 of the Social Security
Act (42 U.S.C. 1395w-22) is amended by adding at the end the
following new subsection:
``(o) Prohibition on Use of Quality-adjusted Life Years.--The
provisions of section 1182(e) shall apply to the utilization of a
dollars-per-quality adjusted life year or similar measure (as described
in such section) by an MA plan in the same manner as such provisions
apply to the utilization of such a year or measure by the Secretary
under this title.''.
(4) Medicare part d.--Section 1860D-12 of the Social Security
Act (42 U.S.C. 1395w-112) is amended by adding at the end the
following new subsection:
``(h) Prohibition on Use of Quality-adjusted Life Years.--The
provisions of section 1182(e) shall apply to the utilization of a
dollars-per-quality adjusted life year or similar measure (as described
in such section) by a prescription drug plan in the same manner as such
provisions apply to the utilization of such a year or measure by the
Secretary under this title.''.
(c) Implementation.--The amendments made by this section shall apply
beginning on January 1, 2025.
Purpose and Summary
This bill prohibits all federal health care programs,
including the Federal Employees Health Benefits Program, and
federally funded state health care programs (e.g., Medicaid)
from using prices that are based on quality-adjusted life years
or other similar measures to determine relevant thresholds for
coverage, reimbursements, or incentive programs.
Background and Need for Legislation
Quality Adjusted Life Years (QALYs) are a cost-
effectiveness measurement used by health care payers as a means
to determine the value and necessity in paying for a treatment
or prescription drug. When using QALYs, payers will assign a
relative value to a beneficiary's life and the value gained
from offering a particular course of treatment for the
individual, relative to the cost of the treatment.
While managing costs for treatments remains a priority for
everyone, the practice of assigning a particular value to a
beneficiary's life and the relative value a treatment would
provide has been cited frequently by the disability community
as a cause for concern that could lead to an undermining of
access to care for people with disabilities if their lives are
undervalued and considered not worth receiving care. Because of
these concerns, Medicare is already prohibited from using QALYs
and other similar, discriminatory measures.\1\ Groups,
including the nonpartisan National Council on Disability,
however, have called for an extension of Medicare's prohibition
on using QALYs and other similar measures to other federal
health care programs, like Medicaid, to stop further
discrimination.\2\
---------------------------------------------------------------------------
\1\42 USC 1320e-1(e).
\2\https://ncd.gov/sites/default/files/
NCD_Quality_Adjusted_Life_Report_508.pdf.
---------------------------------------------------------------------------
H.R. 485 would extend Medicare's current prohibition on
using QALYs and other similar measures to all federal health
care programs, defined as those under 42 U.S.C. 1320a-7b, while
also including the definition of the Federal Employees Health
Benefits Program.
Committee Action
On February 1, 2023, the Subcommittee on Health held a
hearing on H.R. 485. The Subcommittee received testimony from:
Kandi Pickard, National Down Syndrome
Society
Frederick Isasi, Families USA
On March 8, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 485, as amended, to the full
Committee by a voice vote. On March 23, 2023, the full
Committee on Energy and Commerce met in open markup session and
ordered H.R. 485, as amended, favorably reported to the House
by a recorded vote of 27 yeas and 20 nays and 1 present.
Committee Votes
The following reflects the record votes taken during the
Committee consideration:
Oversight Findings and Recommendations
Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of
rule XIII, the Committee held a hearing and made findings that
are reflected in this report.
New Budget Authority, Entitlement Authority, and Tax Expenditures
Pursuant to clause 3(c)(2) of rule XIII, the Committee
finds that H.R. 485 would result in no new or increased budget
authority, entitlement authority, or tax expenditures or
revenues.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
prohibit the usage of QALYs and other similar measures in
federal health care programs.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 485 is known to be duplicative of another Federal program,
including any program that was included in a report to Congress
pursuant to section 21 of Public Law 111-139 or the most recent
Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 485:
On February 1, 2023, the Subcommittee on Health held a
hearing on H.R. 485. The Subcommittee received testimony from:
Kandi Pickard, National Down Syndrome
Society
Frederick Isasi, Families USA
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 485 contains no earmarks, limited tax
benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``Protecting Health
Care for All Patients Act of 2023.''
Section 2. Prohibiting the use of quality-adjusted life years and
similar measures in coverage and payment determinations under
Federal health care programs
Section 2 includes language prohibiting the use of the
quality-adjusted life years and similar measures in coverage
and payment determinations under federal health care programs.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
SOCIAL SECURITY ACT
* * * * * * *
TITLE XI--GENERAL PROVISIONS, PEER REVIEW, AND ADMINISTRATIVE
SIMPLIFICATION
* * * * * * *
Part D--Comparative Clinical Effectiveness Research
* * * * * * *
limitations on certain uses of comparative clinical effectiveness
research
Sec. 1182. (a) The Secretary may only use evidence and
findings from research conducted under section 1181 to make a
determination regarding coverage under title XVIII if such use
is through an iterative and transparent process which includes
public comment and considers the effect on subpopulations.
(b) Nothing in section 1181 shall be construed as--
(1) superceding or modifying the coverage of items or
services under title XVIII that the Secretary
determines are reasonable and necessary under section
1862(l)(1); or
(2) authorizing the Secretary to deny coverage of
items or services under such title solely on the basis
of comparative clinical effectiveness research.
(c)(1) The Secretary shall not use evidence or findings from
comparative clinical effectiveness research conducted under
section 1181 in determining coverage, reimbursement, or
incentive programs under title XVIII in a manner that treats
extending the life of an elderly, disabled, or terminally ill
individual as of lower value than extending the life of an
individual who is younger, nondisabled, or not terminally ill.
(2) Paragraph (1) shall not be construed as preventing the
Secretary from using evidence or findings from such comparative
clinical effectiveness research in determining coverage,
reimbursement, or incentive programs under title XVIII based
upon a comparison of the difference in the effectiveness of
alternative treatments in extending an individual's life due to
the individual's age, disability, or terminal illness.
(d)(1) The Secretary shall not use evidence or findings from
comparative clinical effectiveness research conducted under
section 1181 in determining coverage, reimbursement, or
incentive programs under title XVIII in a manner that
precludes, or with the intent to discourage, an individual from
choosing a health care treatment based on how the individual
values the tradeoff between extending the length of their life
and the risk of disability.
(2)(A) Paragraph (1) shall not be construed to--
(i) limit the application of differential copayments
under title XVIII based on factors such as cost or type
of service; or
(ii) prevent the Secretary from using evidence or
findings from such comparative clinical effectiveness
research in determining coverage, reimbursement, or
incentive programs under such title based upon a
comparison of the difference in the effectiveness of
alternative health care treatments in extending an
individual's life due to that individual's age,
disability, or terminal illness.
(3) Nothing in the provisions of, or amendments made by the
Patient Protection and Affordable Care Act, shall be construed
to limit comparative clinical effectiveness research or any
other research, evaluation, or dissemination of information
concerning the likelihood that a health care treatment will
result in disability.
(e) The Patient-Centered Outcomes Research Institute
established under section 1181(b)(1) shall not develop or
employ a dollars-per-quality adjusted life year (or similar
measure that discounts the value of a life because of an
individual's disability or treats extending the life of an
elderly, disabled, or terminally ill individual as of lower
value than extending the life of an individual who is younger,
non-disabled, or not terminally ill) as a threshold to
establish what type of health care is cost effective or
recommended. [The Secretary shall not] A Federal agency
(including the CMI (as described in section 1115A)) or State
may not utilize such an adjusted life year (or such a similar
measure described in the preceding sentence) as a threshold to
determine coverage, reimbursement, or incentive programs [under
title XVIII.] under any Federal health care program (as defined
in section 1128B, except that such term shall include the
health program established under chapter 89 of title 5, United
States Code). Notwithstanding any other provision of law, a
Federal agency (including the CMI) or State may not waive the
application of the provisions of this subsection (or the
provisions of section 1852(o), section 1860D-12(h), section
1902(a)(88), section 1932(b)(9), or section 2102(e)) under
section 1115, section 1115A, or any other demonstration or
waiver authority.
* * * * * * *
* * * * * * *
TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND DISABLED
* * * * * * *
Part C--Medicare+Choice Program
* * * * * * *
benefits and beneficiary protections
Sec. 1852. (a) Basic Benefits.--
(1) Requirement.--
(A) In general.--Except as provided in
section 1859(b)(3) for MSA plans and except as
provided in paragraph (6) for MA regional
plans, each Medicare+Choice plan shall provide
to members enrolled under this part, through
providers and other persons that meet the
applicable requirements of this title and part
A of title XI, benefits under the original
medicare fee-for-service program option (and,
for plan years before 2006, additional benefits
required under section 1854(f)(1)(A)).
(B) Benefits under the original medicare fee-
for-service program option defined.--
(i) In general.--For purposes of this
part, the term ``benefits under the
original medicare fee-for-service
program option'' means, subject to
subsection (m), those items and
services (other than hospice care or
coverage for organ acquisitions for
kidney transplants, including as
covered under section 1881(d)) for
which benefits are available under
parts A and B to individuals entitled
to benefits under part A and enrolled
under part B, with cost-sharing for
those services as required under parts
A and B or, subject to clause (iii), an
actuarially equivalent level of cost-
sharing as determined in this part.
(ii) Special rule for regional
plans.--In the case of an MA regional
plan in determining an actuarially
equivalent level of cost-sharing with
respect to benefits under the original
medicare fee-for-service program
option, there shall only be taken into
account, with respect to the
application of section 1858(b)(2), such
expenses only with respect to
subparagraph (A) of such section.
(iii) Limitation on variation of cost
sharing for certain benefits.--Subject
to clause (v), cost-sharing for
services described in clause (iv) shall
not exceed the cost-sharing required
for those services under parts A and B.
(iv) Services described.--The
following services are described in
this clause:
(I) Chemotherapy
administration services.
(II) Renal dialysis services
(as defined in section
1881(b)(14)(B)).
(III) Skilled nursing care.
(IV) Clinical diagnostic
laboratory test administered
during any portion of the
emergency period defined in
paragraph (1)(B) of section
1135(g) beginning on or after
the date of the enactment of
the Families First Coronavirus
Response Act for the detection
of SARS-CoV-2 or the diagnosis
of the virus that causes COVID-
19 and the administration of
such test.
(V) Specified COVID-19
testing-related services (as
described in section
1833(cc)(1)) for which payment
would be payable under a
specified outpatient payment
provision described in section
1833(cc)(2).
(VI) A COVID-19 vaccine and
its administration described in
section 1861(s)(10)(A).
(VII) A drug or biological
product that is a selected drug
(as referred to in section
1192(c)).
(VIII) Such other services
that the Secretary determines
appropriate (including services
that the Secretary determines
require a high level of
predictability and transparency
for beneficiaries).
(v) Exception.--In the case of
services described in clause (iv),
other than subclauses (IV), (V), and
(VI) of such clause, for which there is
no cost-sharing required under parts A
and B, cost-sharing may be required for
those services in accordance with
clause (i).
(vi) Prohibition of application of
certain requirements for covid-19
testing.--In the case of a product or
service described in subclause (IV) or
(V), respectively, of clause (iv) that
is administered or furnished during any
portion of the emergency period
described in such subclause beginning
on or after the date of the enactment
of this clause, an MA plan may not
impose any prior authorization or other
utilization management requirements
with respect to the coverage of such a
product or service under such plan.
(2) Satisfaction of requirement.--
(A) In general.--A Medicare+Choice plan
(other than an MSA plan) offered by a
Medicare+Choice organization satisfies
paragraph (1)(A), with respect to benefits for
items and services furnished other than through
a provider or other person that has a contract
with the organization offering the plan, if the
plan provides payment in an amount so that--
(i) the sum of such payment amount
and any cost sharing provided for under
the plan, is equal to at least
(ii) the total dollar amount of
payment for such items and services as
would otherwise be authorized under
parts A and B (including any balance
billing permitted under such parts).
(B) Reference to related provisions.--For
provision relating to--
(i) limitations on balance billing
against Medicare+Choice organizations
for non-contract providers, see
sections 1852(k) and 1866(a)(1)(O), and
(ii) limiting actuarial value of
enrollee liability for covered
benefits, see section 1854(e).
(C) Election of uniform coverage
determination.--In the case of a
Medicare+Choice organization that offers a
Medicare+Choice plan in an area in which more
than one local coverage determination is
applied with respect to different parts of the
area, the organization may elect to have the
local coverage determination for the part of
the area that is most beneficial to
Medicare+Choice enrollees (as identified by the
Secretary) apply with respect to all
Medicare+Choice enrollees enrolled in the plan.
(3) Supplemental benefits.--
(A) Benefits included subject to secretary's
approval.--Subject to subparagraph (D), each
Medicare+Choice organization may provide to
individuals enrolled under this part, other
than under an MSA plan (without affording those
individuals an option to decline the coverage),
supplemental health care benefits that the
Secretary may approve. The Secretary shall
approve any such supplemental benefits unless
the Secretary determines that including such
supplemental benefits would substantially
discourage enrollment by Medicare+Choice
eligible individuals with the organization.
(B) At enrollees' option.--
(i) In general.--Subject to clause
(ii), a Medicare+Choice organization
may provide to individuals enrolled
under this part supplemental health
care benefits that the individuals may
elect, at their option, to have
covered.
(ii) Special rule for msa plans.--A
Medicare+Choice organization may not
provide, under an MSA plan,
supplemental health care benefits that
cover the deductible described in
section 1859(b)(2)(B). In applying the
previous sentence, health benefits
described in section 1882(u)(2)(B)
shall not be treated as covering such
deductible.
(C) Application to Medicare+Choice private
fee-for-servic
Minority Views
H.R. 485, the Protecting Health Care for All Patients Act
of 2023, would prohibit the use of the value measurement
Quality Adjusted Life Years (QALYs) and similar measures in
coverage and payment determinations under all Federal health
care programs. Given concerns that the use of the QALY
measurement does not assign an equal value to each life for the
purposes of determining the relative value of a health care
treatment or prescription drug, the use of this measurement,
and similar measures, has been prohibited for the purposes of
determining coverage, reimbursement, or incentive programs
under title XVIII of the Social Security Act.\1\ As a result,
the Medicare program does not utilize the QALY measurement
under current law.
---------------------------------------------------------------------------
\1\42 U.S.C. 1320e-1(e)
---------------------------------------------------------------------------
In addition, the Inflation Reduction Act, which was enacted
on August 16, 2022 and provides the Secretary of Health and
Human Services (HHS) with the authority to negotiate the price
for certain prescription drugs under Medicare, requires that
for the purposes of negotiation ``the Secretary shall not use
evidence from comparative clinical effectiveness research in a
manner that treats extending the life of an elderly, disabled,
or terminally ill individual as of lower value than extending
the life of an individual who is younger, non-disabled, or not
terminally ill.''\2\
---------------------------------------------------------------------------
\2\P.L. 117-169.
---------------------------------------------------------------------------
The prohibition on the use of the QALY measurement in
current law reflects the concern that the measure places a
lower value on treatments which extend the lives of people with
chronic illnesses and disabilities, and the elderly. However,
the legislation, as amended, could incorrectly be construed in
such a way to create a chilling effect on Federal health
programs' ability to utilize other value measures that are not
discriminatory that are intended to evaluate the effectiveness
of health care treatments and prescription drugs and lower
costs for the Federal government and for the American people.
During the markup of H.R. 485, the Committee considered an
amendment that would prohibit the use of the QALY measurement,
while emphasizing that the Federal government and states can
continue to utilize measures that ``values each year of
extended life equally, irrespective of whether the individual
is elderly, disabled, or terminally ill.'' This amendment would
have reiterated that such measures are nondiscriminatory and
encouraged federal healthcare programs to utilize
nondiscriminatory measures like these for the purposes of
determining value under Federal health programs.
Unfortunately, this amendment to the underlying bill was
not agreed to. It is imperative that the Federal government
effectively determine the value of health care treatments and
prescription drugs in order to ensure Federal health programs
are good stewards of taxpayer dollars and are paying for
effective treatments and cures based on demonstrated value. For
these reasons, I oppose H.R. 485.
Frank Pallone, Jr.,
Ranking Member.
[all]